Earlier this month, we attended the AACR conference Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, which highlighted many recent pre-clinical advancements in the treatment of ovarian cancer. Much of the … Continued
In January’s State of the Union Address, President Obama ushered in an exciting phase in new medical research by introducing the Precision Medicine Initiative (PMI). This initiative will expand our … Continued
(October 15, 2015) According to a Japanese study published in Cancer, BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history. The researchers examined 95 … Continued
(October 7, 2015) A report published in JAMA Oncology shows that most commercially insured women who underwent BRCA genetic testing did not receive genetic counseling by trained genetics professionals. Lack … Continued
(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy … Continued
By Annie Ellis: On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Click plus sign to read more.
By Annie Ellis On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the … Continued
(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II … Continued
Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the … Continued
(9/11/15) By Alan D. D’Andrea, MD, Dana-Farber Cancer Institute and Harvard Medical School, and Elizabeth M. Swisher, MD, University of Washington September is Ovarian Cancer Awareness Month, when we scientists … Continued
The largest private funder of ovarian cancer research awarded $6.3 million in grants while also launching new events and partnerships (September 11, 2015) –Ovarian Cancer Research Fund (OCRF), has awarded … Continued
Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.
Get email updates about research news, action alerts, and ways to join the fight.
